Raymond James Financial reaffirmed a strong-buy rating and Morgan Stanley set a $25.00 price objective for VIR Biotechnology.

The entities involved

• VIR Biotechnology →

  biotech company

  • Astellas Pharma and VIR Biotechnology announced a collaboration to develop a PSMA-targeted T-cell engager.Mon 05:36
• Raymond James Financial →

  American Investment Bank and Financial Services Firm

  • Raymond James Financial began covering Palisade Bio, Inc. on October 13, 2026.14:03
  • Bank of America, Raymond James Financial, and Citigroup issued rating updates and coverage on AxoGen shares.07:44
• Morgan Stanley →

  U.S. investment bank

  • Morgan Stanley and Jefferies Financial Group raised their ratings and price objectives for PTC Therapeutics.18:26
  • BNP Paribas and Morgan Stanley have been appointed to handle a share sale for Jio.15:43

Related events

• Raymond James Financial restated a strong-buy rating and Truist Financial assumed coverage on Construction Partners shares.Jul 9
• Raymond James Financial and TD Cowen issued rating updates for GDS, alongside an insider transaction disclosure filed with the SEC.Sep 7
• Raymond James Financial reiterated an outperform rating on FinWise Bancorp.Sep 7
• Raymond James Financial issued a strong-buy rating on Liquidia Corporation on June 6, 2026.Jun 10
• Raymond James Financial, Jefferies Financial Group, and CIBC raised price targets and objectives for Tamarack Valley Energy Ltd.Sep 12